AAPP is working hard to standardize and improve clinical research through various initiatives, and the awarding of this grant represents a significant milestone in the multi-phase initiative. The mission of the American Association of Psychiatric Pharmacists (AAPP) is to advance the reach and practice of psychiatric pharmacy and serve as the voice of the specialty. High quality research that supports the integration of psychiatric pharmacists into mental health care teams is critical for the advancement of the profession. The primary goal of this funded research is to generate high-quality large sample size (n) data sets that evaluate the impact of integrating psychiatric pharmacists into team-based mental health care in studies with multiple research sites and investigators.
2026 Retrospective Research Grants
To support quality retrospective research, the Outcomes Research Committee has developed three study designs that attempt to isolate the impact of BCPPs on patient-level outcomes. AAPP and the AAPP Foundation are providing $15,000 grants to support research time and to encourage implementation of studies answering research questions of particular importance to the association. Final RFPs will be released soon, along with Q&A. The draft titles of the 2026 studies are:
- BCPP Impact on Medication Therapy Problems and Cost Avoidance in the Treatment of Bipolar Disorder
- Evaluation of Outcomes after Outpatient Clozapine Initiation by Board-Certified Psychiatric Pharmacists (BCPP) Versus Non-BCPP Providers: A Retrospective Cohort Study
- BCPP Pharmacist Management of Opioid Use Disorder (OUD) Following Acute Inpatient or Emergency Department Encounters Versus Usual Care
More information coming soon!
Past Recipients: Prospective Research Grants
In 2023, AAPP committed up to $500,000 to directly support multi-site research related to the impact of psychiatric pharmacists on patient care through the AAPP Foundation.
In 2024, the Foundation awarded $247,352 to the project, "Psychiatric pharmacist management of cardiometabolic risk for adults with serious mental illness in outpatient safety-net mental health clinics in San Francisco." The primary investigator and co-investigators are Esti Iturralde, PhD, Anne Rosenthal, MD, and Hannah Van Ochten, PharmD of Kaiser Permanente Northern California Division of Research.
In 2025, the Foundation awarded $249,786 to the project, “Alternate Prescriber Type - Depression Management (Trial APT-DM): Impact of Psychiatric Pharmacist on Major Depressive Disorder in Primary Care” The co-principal investigators are Dr. Nathaniel Rickles (UConn School of Pharmacy), Dr. Wilner Samson (Hartford Healthcare), and Dr. Charles Caley (Western New England University College of Pharmacy and Health Sciences).